Close

Credit Suisse Starts Biogen (BIIB) at Neutral

January 20, 2016 6:35 AM EST Send to a Friend
Credit Suisse initiates coverage on Biogen (NASDAQ: BIIB) with a Neutral rating and a price target of $322.00.Analyst Alethia Young ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login